« Back
Hydrogels Deliver CAR-T cells For Solid Tumor Treatment
Poster Title: Hydrogels Deliver CAR-T cells For Solid Tumor Treatment
Submitted on 03 Nov 2022
Author(s): Sally Zou
Affiliations: Hunan Huateng Pharmaceutical Co. Ltd.
Poster Views: 64
View poster »

Poster Information
Abstract: The full name of CAR-T gene therapy is Chimeric Antigen Receptor (CAR) T-cell Therapy. Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy in which T cells are taken from a patient's blood and placed in a laboratory setting to be modified so that they can recognize and destroy specific cancer cells. The modified T cells are then delivered back to the patient. Once back in the patient, the modified T cells can detect cancer cells and destroy the cancer by harnessing the body's own immune response. Since 2017, several CAR-T therapies approved for marketing are related to the treatment of hematological tumors. In the treatment of solid tumors, CAR-T has not yet achieved substantial breakthroughs.

3D hydrogel is a star carrier in the field of drug delivery. Through tunable material and structure design, it can not only mimic the native extracellular matrix (ECM) of immune tissues to maintain cell viability, but also deliver to the defense sites in the body in real time to prolong the residence time of carrying cells, thus improving the effect of immunotherapy. Could hydrogel-loaded CAT-T cells bring CAR-T therapy one step closer to solid tumors?

1. Nature Biomedical Engineering (IF=29.234) : Local controlled release of immune cells based on "cell warehouse" for CAR-T therapy of solid tumors; 2021.4.26
CAR-T cell therapy has encountered many setbacks in the treatment of solid tumors, largely due to the physiological barrier of solid tumors and the immunosuppressive nature of the tumor microenvironment, which inhibit the activity and survival of CAR-T cells. Using methacrylylated hyaluronic acid (HAMA) hydrogel as a carrier, the researchers combined CAR-T cells targeting CSPG4 antigen (melanoma-specific antigen) and anti-PDL1 blocking antibody-bound human platelets (P- aPDL1) loaded into the hydrogel. To support the viability and proliferation of CAR-T cells in the hydrogel, PLGA nanoparticle-packaged cytokine IL-15 was also incorporated. This method can be used in combination with other therapies (such as chemotherapy and radiotherapy) to better inhibit tumor recurrence and metastasis. At the same time, the novel cell delivery strategy also provides new ideas for the treatment of other cell therapies and related diseases.


Original article:

Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets

https:/ / s41551-021-00712-1

2. Nature cancer (IF=23.177): Hydrogel assists CAR-T therapy with significant curative effect in the treatment of eye cancer; 2020.8.12
Retinoblastoma (RB) is a pediatric retinal tumor that overexpresses the ganglioside GD2. Although early diagnosis can be treated, patients may lose one or two eyes. The researchers selected chitosan-polyethylene glycol (PEG) thermosensitive hydrogel as the best injectable hydrogel for intraocular delivery of CAR-T (GD2-specific chimeric antigen receptor T lymphocytes). Most of the T cells encapsulated in the hydrogel remained viable and were released from the gel to the outside within 1 week. The experiments found that when combined with locally released interleukin-15 and injected hydrogel GD2, CAR-T successfully eliminated RB tumor cells without compromising vision in mice.


Original article:

GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision

https:/ / s43018-020-00119-y
Summary: In the treatment of solid tumors, CAR-T has not yet achieved substantial breakthroughs. Could hydrogel-loaded CAT-T cells bring CAR-T therapy one step closer to solid tumors?Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons